Of the same authors
Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial (2021)
Another Publication in an International Scientific Journal
Packer, M; Zannad, F; Butler, J; Filippatos, G; Ferreira, JP; Pocock, SJ; Brueckmann, M; Zeller, C; Hauske, S; Anker, SD
Empagliflozin and Major Renal Outcomes in Heart Failure (2021)
Another Publication in an International Scientific Journal
Packer, M; Butler, J; Zannad, F; Pocock, SJ; Filippatos, G; Ferreira, JP; Brueckmann, M; Jamal, W; Zeller, C; Wanner, C; Anker, SD
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial (2022)
Article in International Scientific Journal
Doehner, W; Anker, SD; Butler, J; Zannad, F; Filippatos, G; Ferreira, JP; Salsali, A; Kaempfer, C; Brueckmann, M; Pocock, SJ; Januzzi, JL; Packer, M
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials (2020)
Article in International Scientific Journal
Zannad, F; Ferreira, JP; Pocock, SJ; Anker, SD; Butler, J; Filippatos, G; Brueckmann, M; Ofstad, AP; Pfarr, E; Jamal, W; Packer, M
See all (31)